2021 ASCO Conference Schedule Preview 1 (June 4)

Pay attention to the highlights of this ASCO :

• At the opening ceremony, ASCO Chairman Dr.
  
  Molecular Targeted Drugs and Tumor Biology (June 4th at 11:00 pm) Molecular Targeted Drugs and Tumor Biology (June 4th at 11:00 pm)Molecular Targeting

  1.

  
  1.
  
  immunity

  2.

  
  2.
  
  

  3.

  
  3.
  
  

  4.

  
  4.
  
  

  5.

  
  5.
  
  FDA Breast Cancer Gastric Cancer

  6.

  
  6.
  
  

  7.

  
  7.
  
  Lymphoma Ovarian Cancer Diagnosis

  8.

  
  8.
  Phase Ib trial of Belvarafenib combined with cobimetinib in the treatment of patients with advanced solid tumors

  9.
  BOS172738, a highly effective and selective RET inhibitor

  9.
  BOS172738, a highly effective and selective RET inhibitor

  RET gene alterations (mutations and fusions) have kinase activity and are detected in many tumors, including NSCLC , medullary thyroid cancer, colon, breast and ovarian cancer.
  There is currently no targeted drug for RET gene mutations.
  BOS172738 was developed by Boston Pharmaceuticals.
  

  NSCLC

  ASCO/European Society of Medical Oncology (ESMO) Joint Conference: Pancreatic Cancer-Challenges and Future Directions

  ASCO/European Society of Medical Oncology (ESMO) Joint Conference: Pancreatic Cancer-Challenges and Future Directions ASCO/European Society of Medical Oncology (ESMO) Joint Conference: Pancreatic Cancer-Challenges and Future Directions

  (11:00 pm-12:15 am, June 4)

  (11:00 pm on June 4th-12:15 am) (11:00 pm on June 4th-12:15 am)
  • Epidemiology and genetics of pancreatic cancer
  • Treatment strategies for resectable pancreatic cancer
  • The treatment strategy of borderline resectable pancreatic cancer
  • New treatments for pancreatic cancer
• Epidemiology and genetics of pancreatic cancer
• Treatment strategies for resectable pancreatic cancer
• The treatment strategy of borderline resectable pancreatic cancer
• New treatments for pancreatic cancer

FDA approved and clinical trials (from 11:00 pm to 1:00 am on June 4)

FDA approval and clinical trials (11:00 pm-1:00 am on June 4) FDA approval and clinical trials (11 pm-1:00 am on June 4)
• The prominent role of Sacituzumab in triple-negative breast cancer
• HER2 targeted therapy for solid tumors: Margetuximab-Cmkb, Tucatinib and Trastuzumab Deruxtecan
• RET, MET and KRAS-new targeted therapies for lung cancer and other cancers
• Expand the indications of CAR-T cell immunotherapy.
  Brexucabtagene Autoleucel in the treatment of mantle cell lymphoma
• The prominent role of Sacituzumab in triple-negative breast cancer
• HER2 targeted therapy for solid tumors: Margetuximab-Cmkb, Tucatinib and Trastuzumab Deruxtecan
• RET, MET and KRAS-new targeted therapies for lung cancer and other cancers
• Expand the indications of CAR-T cell immunotherapy.
  Brexucabtagene Autoleucel in the treatment of mantle cell lymphoma
CAR-T

leave a message here